13200-35-6

Basic information

• Product Name: (2S,6R)-2,6-dimethylpiperidin-4-one
• Synonyms: (2S,6R)-2,6-dimethylpiperidin-4-one;(2S,6R)-2,6-dimethylpiperidin-4-one hydrochloride;cis-2,6-Dimethyl-4-oxo-piperidine;cis-2,6-Dimethylpiperidin-4-one;4-Piperidinone, 2,6-dimethyl-, cis-
• CAS NO: 13200-35-6
• Molecular Formula: C7H13NO
• Molecular Weight: 127.18422
• EINECS: -0
• Mol File: 13200-35-6.mol

Chemical Properties

• Boiling Point: 99-105 °C(Press: 25 Torr)
• Appearance: /
• Density: 0.915±0.06 g/cm3(Predicted)
• PKA: 9.07±0.60(Predicted)
• CAS DataBase Reference: (2S,6R)-2,6-dimethylpiperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,6R)-2,6-dimethylpiperidin-4-one(13200-35-6)
• EPA Substance Registry System: (2S,6R)-2,6-dimethylpiperidin-4-one(13200-35-6)

Safety Data

• Hazardous Substances Data: 13200-35-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,6R)-2,6-dimethylpiperidin-4-one is utilized as a building block in organic synthesis for its unique structure and reactivity, allowing for the creation of a variety of complex organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2S,6R)-2,6-dimethylpiperidin-4-one is used as a precursor for the preparation of various pharmaceuticals. Its specific stereochemistry and functional groups make it a key component in the synthesis of drugs with targeted therapeutic effects.
Used in Agrochemical Industry:
(2S,6R)-2,6-dimethylpiperidin-4-one also serves as a precursor in the agrochemical industry, where it is used in the development of compounds for agricultural applications, such as pesticides and herbicides, leveraging its structural properties to enhance the effectiveness of these products.
Used in Other Organic Compounds:
Beyond its applications in synthesis and industry, (2S,6R)-2,6-dimethylpiperidin-4-one is used as a precursor for the preparation of other organic compounds, highlighting its versatility and importance in the realm of organic chemistry.

Upstream product

• 198211-15-3 (2R,6S)-1-benzyl-2,6-dimethylpiperidin-4-one 
• 75-07-0 acetaldehyde 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 

Downstream Products

• 1005397-64-7 tert-butyl-cis-2,6-dimethyl-4-oxopiperidine-1-carboxylate 
• 1268816-80-3 trans-2,6-dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Farnesoid X receptor (FXR) stimulant

The invention belongs to the technical field of medicines, and particularly relates to a compound as shown in the formula (I), and pharmaceutically acceptable salt and ester or a stereisomer thereof.R1, R2, R3, R4, W, A, Z, E, X, Y and n are as defined in

AMINOPYRIMIDINES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula( I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula ( I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

Novel kinase inhibitors

The present invention relates to a novel kinase inhibitor useful as a medicine for tumor, nerve disorder and mental illness. The purpose of the present invention is to provide a compound having improved blood-aqueous barrier penetrability to neurodegenerative diseases that cancer spreads to brain or progresses in brain. To this end, provided is a compound represented by chemical formula 1 or a pharmaceutically allowable salt thereof.COPYRIGHT KIPO 2017

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.